Announced Tue, 11 Aug · 14:55 IST
Board meeting on Aug 14, 2026 to consider Q1 FY27 results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹108.85
prior close
₹111.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
———+0.0+4.0+6.1+8.2+10.3+12.5+17.0————
Up moveDown movePending
AI summary
Parmax Pharma has informed BSE that its Board of Directors will meet on August 14, 2026 to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026. The trading window for insiders is closed until 48 hours after the results announcement.
Likely market impact
Routine regulatory filing. Investors should watch for Q1 results on Aug 14, 2026 for actual performance updates.